Principal Investigator
Kottil Rammohan
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20220833
Clinical Trial Summary
Phase 2/3, Open-label, Historical-controlled, Single-arm, Multicenter Study to Evaluate the Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety of Ravulizumab in Children and Adolescents With Aquaporin-4 antibody Positive (AQP4-Ab [+]) Neuromyelitis Optica Spectrum Disorder (NMOSD).
Phase
TBD
Funding Agency/Sponsor
Industry
Disease
Multiple Sclerosis
Contact Information
Study Contact
Yanet Babcock
Phone Number
+1 (305) 2431088
Email
ybabcock@miami.edu